Drug Profile


Latest Information Update: 26 Feb 2008

Price : $50

At a glance

  • Originator Sheffield Pharmaceuticals
  • Class Antivirals
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 07 Sep 2000 Sheffield Pharmaceuticals has outlicensed the rights to RBC CD4 and is no longer involved in its development
  • 21 Oct 1999 No-Development-Reported for HIV infections treatment in USA (Unknown route)
  • 27 May 1997 Phase-II clinical trials for HIV infections treatment in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top